---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071337"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:40:43.925581+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode shareholders reject reverse stock split; stock plan amendment approved

## Summary
- Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
- Stock plan amendment passed: 526,212 for, 205,773 against; adds 3,000,000 shares for issuance.
- All four director nominees elected (Calais, Fitzgerald, Manting, Marquet) with ~595K-597K votes for.
- Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.

## SEC filing metadata
- accession: 0001104659-24-071337
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924071337/0001104659-24-071337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924071337/tm2417255d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071337
- JSON: https://secwatch.observer/filing/0001104659-24-071337.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.